Literature DB >> 10767132

Antithrombotic Therapy in Stroke Prevention and Treatment: A Review.

.   

Abstract

Current knowledge of antithrombotic therapy based on controlled clinical trials has revolutionized the way clinicians approach stroke prevention and treatment. This review article addresses the pathogenesis of stroke and summarizes information from clinical trials regarding the use of antiplatelet agents, heparin, warfarin (particularly in nonvalvular atrial fibrillation), and thrombolytics in stroke prevention and treatment.

Entities:  

Year:  1998        PMID： 10767132     DOI： 10.1023/a:1013289004656

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  13 in total

Review 1.  Anticoagulation: risks and benefits in atrial fibrillation.

Authors:  L D Fiore
Journal:  Geriatrics       Date:  1996-06

Review 2.  Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management.

Authors:  J E Ansell; R Hughes
Journal:  Am Heart J       Date:  1996-11       Impact factor: 4.749

Review 3.  Primary prevention of stroke.

Authors:  L L Bronner; D S Kanter; J E Manson
Journal:  N Engl J Med       Date:  1995-11-23       Impact factor: 91.245

Review 4.  Drugs and surgery in the prevention of ischemic stroke.

Authors:  H J Barnett; M Eliasziw; H E Meldrum
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  Ventricular dysfunction and the risk of stroke after myocardial infarction.

Authors:  E Loh; M S Sutton; C C Wun; J L Rouleau; G C Flaker; S S Gottlieb; G A Lamas; L A Moyé; S Z Goldhaber; M A Pfeffer
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

6.  The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.

Authors:  M Gent; J A Blakely; J D Easton; D J Ellis; V C Hachinski; J W Harbison; E Panak; R S Roberts; J Sicurella; A G Turpie
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Stroke Prevention in Atrial Fibrillation Study. Final results.

Authors: 
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

9.  Medical treatment for stroke prevention.

Authors:  D B Matchar; D C McCrory; H J Barnett; J R Feussner
Journal:  Ann Intern Med       Date:  1994-07-01       Impact factor: 25.391

10.  Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.

Authors: 
Journal:  N Engl J Med       Date:  1995-07-06       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.